Anti-aging: NAD+, a Metabolite, Headed for Human Trials

Anti-aging: NAD+, a Metabolite, Headed for Human Trials

Anti-aging: NAD+, a Metabolite, Headed for Human Trials

Medical researchers have discovered a naturally occurring compound the human body produces that can speed DNA repair, combat disease, and may turn back the clock on aging.

The compound called NAD+, which is present in all cells plays a Key role in regulating protein interactions that control DNA repair.

An international group of scientists predicts the team’s discovery of NAD+ will lead to a new drug to reverse aging, speed DNA repair, and even keep astronauts healthy on long space flights.

A leading member of research team, geneticist Dr. David Sinclair, whose team is based at Harvard Medical School and the University of New South Wales in Sydney, Australia said the first human trials of a therapy based on the compound will begin within 6 months.

25 volunteers will be injected with a substance to verify its health and longevity benefits. If the trial turns out successfully, larger scale human trials will be conducted in the United States, Australia, and possibly other countries.

“Then we really get serious,” Dr. Sinclair declared

NAD+ is what’s known as a metabolite, a substance naturally found in our bodies which are vital for metabolism. It is present in all cells and plays a key role as a regulator in protein-to-protein interactions controlling DNA repair.

Sinclair’s laboratory research involved using NMN — a NAD+ precursor or “booster” which the team has shown is successful in improving cells’ ability to repair DNA damage caused by radiation exposure, including Sunlight, and old age.

The team’s lab work found that mice, injected with NMN, appeared more youthful at the cellular level in a variety of standard biological tests.

“The cells of the old mice were indistinguishable from the young mice after just one week of treatment,” Dr. Sinclair says.

“This is the closest we’ve come to a safe and effective anti-aging drug that’s perhaps only three to five years away from being on the market, if the human trials go well.”

The research project has come to the attention of the National Aeronautics and Space Administration (NASA), which has asked to be kept fully briefed on progress because of the possibility of using the substance to keep its astronauts healthy during long space missions, which can speed up aging processes.

According to Dr. Lindsay Wu, a University of New South Wales-based member of the research team, 96% of childhood cancer survivors suffer a chronic disease by age 45.

These include cardiovascular diseases, Type 2 diabetes, Alzheimer’s disease, and various cancers unrelated to their childhood cancers.

“All of this adds up to the fact they have accelerated aging, which is devastating,” Dr. Wu says. “It would be great to do something about that, and we believe we can with this molecule.”

For the past 4 years, Doctors Sinclair, Wu, and others on the research team have been working with biomedical companies with the aim of making NMN into a drug substance that can be used on patients. It will act by boosting the effectiveness of the body’s own NAD+.
The research was reported in a recent issue of the journal Science.

As well as delaying the onset of visible signs of aging, Dr. Sinclair believes the compound could have a great “impact on health and longevity.”

“We took mice that were 20 months old, which is equivalent to a 60- 70 year-old human and we gave them NMN and we found that . . . many aspects of aging were reversed,” Sinclair notes.

“Their DNA repair activities went up to youthful levels and they were more resistant to radiation and should therefore be more protected against cancer and aging itself.”

Meantime…

Eat healthy, Be healthy, Live lively

The following two tabs change content below.

Paul Ebeling

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of “The Red Roadmaster’s Technical Report” on the US Major Market Indices™, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

Latest posts by Paul Ebeling (see all)

You must be logged in to post comments :  
CONNECT WITH